PET and PK analysis of the humanized monoclonal anti-VEGF antibody HuMV833. An EORTC-biological treatment development group phase I study

Jayson, Gordon C; Zweit, Jamal; Mulatero, C; Hastings, D. L.; Julyan, PJ; Ranson, Malcolm R; Lawrance, Jeremy A L; McGown, AT; Jackson, A.; Hakannson, L; Wagstaff, John; Groenwegen, G.; Lehmann, F.; Levitt, Dan; Tang, Tiffany; Zweirzina, H.

doi:10.1016/s0959-8049(01)80467-6

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

PET and PK analysis of the humanized monoclonal anti-VEGF antibody HuMV833. An EORTC-biological treatment development group phase I study

Cited by 2 publications

References 0 publications

Current and Future Therapeutic Targets of the Tumour-Host Microenvironment

Current and Future Therapeutic Targets of the Tumour-Host Microenvironment

Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media

Contact Info

Product

Resources

About